IMAC
Simplifying the Market Launch of Innovative Therapeutics

Worldwide, access to highly specialised drugs, therapies, and treatments is critical for patients. However, launching new therapeutics and medical devices in global markets is demanding for pharmaceutical, medical device, and biotechnology companies. Challenges exist at many levels—especially for rare diseases, for which limited data are available from smaller patient groups and inadequate disease knowledge often exists among payers. Companies need robust strategies to demonstrate a product’s overall benefit, including clinical efficacy, safety, and cost effectiveness, during the health technology assessment (HTA) review. This often includes the need for real world evidence (RWE) to support the submission to reimbursement agencies.

International Market Access Consulting (IMAC), a specialist in market access consulting for pharmaceutical and biotech companies, brings unmatched expertise to overcome the challenges of obtaining reimbursement for therapeutic products. The boutique consulting firm develops strategic solutions for market access reimbursement for therapeutics across a wide range of indications, specialising in oncology and rare diseases.

IMAC’s team of experienced industry and consulting professionals provides a complete range of market access services, including HTA dossier planning and strategy, such as the development of the value story, clinical summary, systematic literature review, economic modelling, indirect treatment comparison, and network meta-analysis.

“We support clients throughout the HTA submission process, providing them with a comprehensive solution from strategy to execution at every level,” says Louise Perrault, President and CEO of IMAC.

Perrault founded IMAC with a vision to create a consulting group of experts extending their full support to clients seeking market access. IMAC takes a holistic approach that promotes the value proposition of the target therapy in HTA dossiers, builds a strong case for reimbursement, and greatly improves the opportunity for uptake in local markets.

A valuable partner to pharma, medical device, and biotech companies, IMAC’s collaborations with global specialists and strategic partners augment its services and enables the delivery of excellence, integrity, and quality in HTA submissions across 28 countries.

Extensive experience in developing inclusive RWE generation strategies defines IMAC’s market access offerings. Generating RWE improves the comparative analysis of efficacy, safety, and costeffectiveness of a target product, and enhances the communication of overall value during the HTA process, increasing the opportunity for a successful launch.

IMAC specializes in the development of innovative health economic models. For the most complex, rare disease therapeutics, these models bridge the knowledge gap among key reviewers, payers, and decision-makers in the HTA process, enabling them to expedite their approval for market access reimbursement.

The benefits of the IMAC team’s cumulative experience are ideally sought by clients during the early phases of product development; however, when clients reach out to IMAC in later stages, their proactive team excels at preparing dossiers that maximise chances for reimbursement.

IMAC has an unparalleled history of success with challenging market access cases. An instance that best showcases IMAC’s capabilities is engagement with a pharma company on the verge of introducing a new drug—without randomised controlled trials—for treatment of a rare disease. IMAC identified the best strategy and implemented a plan to generate RWE, which strengthened the dossier for HTA review, and ultimately led to reimbursement. IMAC leveraged this success to develop reimbursement dossiers for all major European countries and North America.

As a testament to IMAC’s strength in market access planning in the EU, they were invited to participate in a €6 million grant from the European Commission for an innovative liver failure treatment.

Scripting numerous successful reimbursement stories, IMAC is well positioned to streamline and expedite market access for the latest rare disease therapeutics with the ultimate goal of assisting clients in improving patients’ quality of life.